Patent · US Active

Estrogen receptor modulators for treating mutants

US11278532B2 · kind B2 · utility

0Cited by

0References

22Claims

0Family size

Assignee

Recurium IP Holdings, LLC · US

Inventors

Ahmed Abdi Samatar · Plainsboro, US
Jiali Li · San Diego, US
Jianhui Ma · San Diego, US
Sayee Gajanan Hegde · San Diego, US
Peter Qinhua Huang · San Diego, US
Kevin Duane Bunker · San Diego, US
Fernando Donate · San Diego, US

Key dates

Filing date	Aug 4, 2020
Grant date	Mar 22, 2022
Priority date	—
Expiry date	Aug 4, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERα).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.